Clinical Trial Update: Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pegloticase (KRYSTEXXA) in patients on hemodialysis due to chronic kidney disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Sponsor: Savient Pharmaceuticals | Conditions: Chronic Kidney Disease Stage 5 | Phase 1 | Status: COMPLETED